NASDAQ:PTGX

Protagonist Therapeutics Stock Insider Trading

etoro logo Buy PTGX
*Your capital is at risk
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026

Protagonist Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -84.03. In total, the insiders bought 1.16M and sold 569.31K PTGX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-84.03
Buy 1.16M shares
Sell 569.31K shares
61% Buy Activity
Weak Positive Correlation
Sell Signal Medium Confidence
Jan 20, 2026

Analysis Breakdown:

  • Strongly supported by a very low Insider Power Score of -84.03.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Mar 26, 2026
Buy
Stock Option (right to buy)
M-Exempt
Molina Arturo Md
Chief Medical Officer
Officer 15 000
Value: $120.6K
Mar 26, 2026
Buy
Common Stock
M-Exempt
Selick Harold E
Director
Director 24 000
Value: $309.1K
Mar 25, 2026
Buy
Common Stock
M-Exempt
Patel Dinesh V Ph D
President And CEO
CEO / President 54 641
Value: $468.8K
Mar 25, 2026
Sell
Common Stock
S-Sale
Patel Dinesh V Ph D
President And CEO
CEO / President 54 641
Value: $5.52M
Mar 25, 2026
Buy
Stock Option (right to buy)
M-Exempt
Patel Dinesh V Ph D
President And CEO
CEO / President 54 641
Value: $468.8K
Mar 24, 2026
Buy
Stock Option (right to buy)
M-Exempt
Patel Dinesh V Ph D
President And CEO
CEO / President 59
Value: $506
Mar 24, 2026
Buy
Common Stock
M-Exempt
Patel Dinesh V Ph D
President And CEO
CEO / President 59
Value: $506
Mar 23, 2026
Sell
Common Stock
G-Gift
Patel Dinesh V Ph D
President And CEO
CEO / President 50 000
Value: $0
Feb 17, 2026
Sell
Common Stock
S-Sale
Williams Lewis T
Director
Director 18 000
Value: $1.48M
Feb 17, 2026
Buy
Common Stock
M-Exempt
Williams Lewis T
Director
Director 18 000
Value: $195.1K
Feb 17, 2026
Buy
Stock Option (right to buy)
M-Exempt
Williams Lewis T
Director
Director 18 000
Value: $195.1K
Feb 06, 2026
Buy
Stock Option (right to buy)
M-Exempt
Waddill William D.
Director
Director 20 000
Value: $166.2K
Feb 06, 2026
Buy
Common Stock
M-Exempt
Waddill William D.
Director
Director 20 000
Value: $166.2K
Feb 06, 2026
Sell
Common Stock
S-Sale
Waddill William D.
Director
Director 20 000
Value: $1.67M
Jan 27, 2026
Buy
Stock Option (right to buy)
M-Exempt
Molina Arturo Md
Chief Medical Officer
Officer 5 000
Value: $40.2K
Jan 27, 2026
Sell
Common Stock
S-Sale
Molina Arturo Md
Chief Medical Officer
Officer 5 000
Value: $410.0K
Jan 27, 2026
Buy
Common Stock
M-Exempt
Molina Arturo Md
Chief Medical Officer
Officer 5 000
Value: $40.2K
Jan 27, 2026
Buy
Stock Option (right to buy)
M-Exempt
Ali Asif
Chief Financial Officer
C-Suite Officer 16 000
Value: $307.0K
Jan 27, 2026
Sell
Common Stock
S-Sale
Ali Asif
Chief Financial Officer
C-Suite Officer 28 000
Value: $2.33M
Jan 27, 2026
Buy
Stock Option (right to buy)
M-Exempt
Patel Dinesh V Ph D
President And CEO
CEO / President 4 068
Value: $87.8K
Jan 27, 2026
Sell
Common Stock
S-Sale
Patel Dinesh V Ph D
President And CEO
CEO / President 4 068
Value: $338.4K
Jan 27, 2026
Sell
Common Stock
S-Sale
Ali Asif
Chief Financial Officer
C-Suite Officer 18 203
Value: $1.51M
Jan 27, 2026
Buy
Stock Option (right to buy)
M-Exempt
Ali Asif
Chief Financial Officer
C-Suite Officer 12 000
Value: $146.0K
Jan 27, 2026
Buy
Common Stock
M-Exempt
Patel Dinesh V Ph D
President And CEO
CEO / President 4 068
Value: $87.8K
Jan 27, 2026
Buy
Common Stock
M-Exempt
Ali Asif
Chief Financial Officer
C-Suite Officer 12 000
Value: $146.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT PROTAGONIST THERAPEUTICS INC
Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorder...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE